Delisting risk
Galmed Pharmaceuticals (GLMD)
Develops Aramchol candidates and CG-100 for colorectal surgery.
$4.06
Pre-market+0.02 (+0.50%)
At close$4.04(+2.93%)
In millions of USD, except per-share figures
| In millions | Q2 FY23Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | 1 | 2 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 3 | 2 | |
| Research & development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | −2 | −1 | −2 | −1 | −1 | −2 | −2 | −1 | −2 | −2 | −3 | −2 |
| 0 | 0 | 0 | 0 | 0 | 0 | −2 | 0 | 0 | 0 | −2 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 |
| Income before tax | −2 | −1 | −2 | −1 | −1 | −2 | −3 | −1 | −2 | −2 | −5 | −2 |
| Net income from continuing operations | −2 | −1 | −2 | −1 | −1 | −2 | −3 | −1 | −2 | −2 | −5 | −2 |
| Net income | −2 | −1 | −2 | −1 | −1 | −2 | −3 | −1 | −2 | −2 | −5 | −2 |
| EPS, basic | −$0.95 | −$0.24 | −$3.20 | −$1.84 | −$17.04 | −$221.52 | −$371.36 | −$4.96 | −$5.04 | −$2.80 | −$5.84 | −$2.32 |
| EPS, diluted | −$0.95 | −$0.24 | −$3.20 | −$1.84 | −$17.04 | −$221.52 | −$371.36 | −$4.96 | −$5.04 | −$2.80 | −$5.84 | −$2.32 |
| Weighted average shares, basic | 2 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Weighted average shares, diluted | 2 | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| EBITDA | −2 | −1 | −2 | −1 | −1 | −2 | −3 | −1 | −2 | −2 | −5 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −2 | −1 | −2 | −1 | −1 | −2 | −3 | −1 | −2 | −2 | −5 | −2 |